NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock News
$82.44
-1.36 (-1.62%)
At Close: May 03, 2024
BioMarin Pharmaceutical CEO: Substantial Profits Ahead
01:35pm, Friday, 15'th Nov 2019
BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé chats with Jim Cramer about the impact of the recent FDA approval the company received for its hemophilia drug.
BioMarin CEO expects 'substantial' profitability after FDA approval of hemophilia drug
07:09pm, Thursday, 14'th Nov 2019
Jim Cramer chats with Jean-Jacques Bienaimé, chairman and CEO of BioMarin, which focuses on therapies to treat rare diseases.
2 Beaten-Down Biotech Stocks That Could Make You Rich
10:00am, Monday, 11'th Nov 2019
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
Here's Why You Should Add BioMarin Pharmaceutical To Your Portfolio
09:03am, Monday, 04'th Nov 2019
Here's Why You Should Add BioMarin Pharmaceutical To Your Portfolio
